SREBF1 and ovarian carcinoma: In this study, we demonstrate that silencing SREBP1 in ovarian cancer cells leads to decreased glutathione (GSH) levels, reduced protein expression of XCT and GPX4, and increased levels of malondialdehyde (MDA) and lipid peroxidation, indicating that SREBP1 silencing induces ferroptosis in ovarian cancer cells.